The recent phase III trial (NCT03745716) that evaluated APR-246 in combination with azacitidine to treat TP53 mutant myelodysplastic syndrome failed to meet its primary endpoint, finding no significant difference between APR-246 plus azacytidine treatment compared to azacitidine alone. The gene discussed is TP53; the disease is myelodysplastic syndrome.